These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7896180)

  • 1. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
    Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
    Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de Nictolis M; Muzzioli M; Fabris N; Romanini C; Biagini G
    Gynecol Oncol; 1995 Jul; 58(1):28-33. PubMed ID: 7789886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining.
    Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
    Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract.
    Chowdhury GM; Kojima K; Kanayama H; Tsuji M; Kurokawa Y; Kagawa S
    Cancer; 1996 Aug; 78(4):827-33. PubMed ID: 8756378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
    Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant role of MIB1 index in differentiating serous ovarian tumors-preliminary report.
    Frigerio L; Agnello A; Sassi I; Mangili F; Taccagni G; Mariani A; Ferrari A
    Anticancer Res; 1997; 17(2B):1287-92. PubMed ID: 9137487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality control considerations for Ki-67 detection and quantitation in paraffin-embedded tissue.
    Hendricks JB; Wilkinson EJ
    J Cell Biochem Suppl; 1994; 19():105-10. PubMed ID: 7823581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance.
    Marx D; Meden H; Brune T; Kron M; Korabiowska M; Kuhn W; Schauer A
    Anticancer Res; 1997; 17(1B):775-80. PubMed ID: 9066619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
    J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors.
    Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
    Cancer; 1999 May; 85(10):2219-25. PubMed ID: 10326701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB; Iversen OE; Akslen LA
    Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
    Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
    Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
    Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
    Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.